Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
Intervalo de año de publicación
1.
Retina ; 41(10): 2079-2087, 2021 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-34543242

RESUMEN

PURPOSE: To ascertain the pathogenesis of macular hole (MH) associated with age-related macular degeneration (AMD) and its surgical outcomes. METHODS: Patients with full-thickness MH associated with AMD (higher grades than intermediate) were enrolled. The mechanism of MH formation and closure rate after vitrectomy (surgical outcome) were determined using optical coherence tomography imaging. RESULTS: The mechanism of MH formation (35 eyes) associated with AMD was classified into four types: vitreomacular traction (42.9%), gradual retinal thinning caused by subretinal drusen or pigment epithelial detachment (22.9%), massive subretinal hemorrhage (20.0%), and combined (14.3%). In the 41 eyes that underwent vitrectomy, the logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.82 (0.10-2.30) preoperative to 0.69 (0.10-2.30) postoperative (P = 0.001). Successful closure of the MH was achieved in 33 eyes (80.5%) after vitrectomy. No significant association was observed between the closure rate of MH after vitrectomy and mechanism of MH formation (P = 0.083). CONCLUSION: The mechanism of MH formation associated with AMD was classified into four types and was not related to its surgical outcome. Considering visual improvement and surgical outcome after vitrectomy in our study, active surgical treatment can be considered for MH associated with AMD.


Asunto(s)
Atrofia Geográfica/complicaciones , Perforaciones de la Retina/etiología , Perforaciones de la Retina/cirugía , Degeneración Macular Húmeda/complicaciones , Anciano , Endotaponamiento , Femenino , Fluorocarburos/administración & dosificación , Atrofia Geográfica/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Perforaciones de la Retina/diagnóstico por imagen , Perforaciones de la Retina/fisiopatología , Estudios Retrospectivos , Aceites de Silicona/administración & dosificación , Hexafluoruro de Azufre/administración & dosificación , Tomografía de Coherencia Óptica , Resultado del Tratamiento , Agudeza Visual/fisiología , Vitrectomía , Degeneración Macular Húmeda/fisiopatología
2.
J Cataract Refract Surg ; 41(10): 2125-35, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26703288

RESUMEN

PURPOSE: To assess the feasibility of a new injectable telescopic intraocular lens (IOL). SETTING: London Eye Hospital, London, United Kingdom. DESIGN: Prospective interventional pilot study. METHOD: Eyes with bilateral, intermediate, or advanced dry age-related macular degeneration (AMD); preoperative decimal corrected distance visual acuity (CDVA) of 0.25 or less; and improvement with extraocular simulation of the intervention had implantation of 2 IOLs designed for use together in a Galilean telescope configuration (iolAMD). Patients were followed for 4 months. Safety was assessed by monitoring visual acuity, intraocular pressure, specular microscopy, and anterior segment and macular optical coherence tomographies. Fixation stability and macular sensitivity were determined using microperimetry in some eyes. RESULTS: There were no significant intraoperative or postoperative complications. In 1 eye, an anterior sulcus IOL was replaced; there were no sequelae. The mean endothelial cell density was reduced by 18%. The mean decimal CDVA improved from 0.12 preoperatively to 0.20 at 4 months, a 67% gain. The mean change in spherical equivalent after implantation was -1.5 diopters (D) with 0.5 D of induced astigmatism. Microperimetric testing indicated a magnification effect and a deviation of the retinal image by up to 5 degrees, with improved fixation stability. CONCLUSIONS: This injectable intraocular miniature telescope appears safe in the short to medium term and capable of improving visual function. No significant issues were encountered regarding candidate eye selection or patient retention and cooperation. Further work is needed to evaluate the safety and efficacy of the device, particularly with respect to daily-living activities and the range of indications. FINANCIAL DISCLOSURE: Dr. Qureshi has a financial interest in London Eye Hospital Pharma. No other author has a financial or proprietary interest in any material or method mentioned.


Asunto(s)
Atrofia Geográfica/rehabilitación , Implantación de Lentes Intraoculares/métodos , Lentes Intraoculares , Facoemulsificación , Trastornos de la Visión/rehabilitación , Resinas Acrílicas/administración & dosificación , Actividades Cotidianas , Anciano , Anciano de 80 o más Años , Estudios de Factibilidad , Femenino , Atrofia Geográfica/fisiopatología , Humanos , Inyecciones Intraoculares , Cápsula del Cristalino/efectos de los fármacos , Masculino , Proyectos Piloto , Estudios Prospectivos , Seudofaquia/fisiopatología , Tomografía de Coherencia Óptica , Trastornos de la Visión/fisiopatología , Agudeza Visual/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA